The regulator said the Phase 3 study comparator did not reflect the “best-available standard of care,” though it raised no safety or efficacy concerns. ・Moderna said the refusal conflicts with prior ...
Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna ...